Comparison
Citeline runs the largest stack of syndicated pharma databases in the market. Delvant ships bounded custom-scoped deliverables. Same buyers, different shapes of work. This page is for teams choosing between an enterprise subscription stack and a commissioned engagement.
Citeline (part of Norstella since 2022) is the umbrella for a stack of syndicated pharma databases and editorial products: Trialtrove (clinical trial intelligence), Pharmaprojects (drug pipeline tracking), Sitetrove (investigator and site intelligence), Citeline Connect (patient recruitment), Datamonitor Healthcare (analyst reports and forecasts), plus the editorial brands Pink Sheet, Scrip, and In Vivo. Sold primarily as enterprise subscriptions; per-seat and per-product quotes are not public. Datamonitor Healthcare publishes off-the-shelf disease and drug reports priced individually.
Delvant is a bounded custom-intelligence service. Each engagement starts from one or two specific questions a buyer cannot answer with a templated report or a database query, scopes the comparator set, runs a fresh search against locked anchor sources (ClinicalTrials.gov, EMA, FDA, PubMed, EHA, ASH, EULAR, AACR, ASCO, ESMO), tags every claim by provenance tier (Sourced, Inferred, Opinion, Hedged), and ships a 10-30 page deliverable in 5-15 business days. Tier 1 briefs start at EUR 3,500. Tier 2 strategic dossiers run EUR 12,000-35,000.
| Dimension | Citeline | Delvant |
|---|---|---|
| Product shape | Database stack + editorial reports. Always-on subscription model. Buyer queries, filters, exports. | Custom-scoped deliverable. One-to-three commissioned questions per engagement. No log-in, no query interface. |
| Therapeutic area scope | Broad. All major TAs across oncology, autoimmune, cardiovascular, neurology, rare disease, infectious disease, vaccines, gene/cell therapy. | Narrow. Core: rare hematology, immune cytopenias (ITP, AIHA, HDFN), plasma-derived therapeutics. Adjacent: rare oncology, IgG autoimmune, transplant. |
| Methodology transparency | Editorial team + research analysts curate weekly. Methodology described at platform level; per-claim source mapping not exposed inside Datamonitor reports. | Per-claim tier tags (Sourced / Inferred / Opinion / Hedged) visible inline. Methodology section + audit trail in every deliverable. |
| Citation discipline | References listed at the report level; mapping of individual claims to source not disclosed by default. | Every Sourced claim re-verified at the cited URL during Gate A pass. Page-locked references. |
| Trial + site intelligence depth | Deep. Trialtrove and Sitetrove are widely used by clinical operations and site-selection teams across large pharma. Investigator-level data layered in. | Not a tracker. Pulls fresh ClinicalTrials.gov data per engagement, scoped to the comparator set. No standing investigator database. |
| Turnaround | Immediate for database queries. Datamonitor analyst reports run to a publication calendar. | 5 business days (T1). 10-15 business days (T2). Fixed schedule, no rush-fee compression. |
| Indicative price (public) | Not publicly disclosed. Enterprise subscriptions are quoted; full-platform access typically lands in the high five-figure to mid six-figure USD annual range. Individual Datamonitor reports listed on the storefront. | From EUR 3,500 (T1, 1 question, 10-15 pages). EUR 12,000-35,000 (T2, 2-3 questions, 20-30 pages). |
| Custom framing | Limited. Database outputs and editorial reports follow a curated framework. Custom consulting work available via Norstella sister brands (Evaluate, The Dedham Group, MMIT) at separate scope and price. | Default. Scope defined at C1 (Day 1-2 frame check). Mid-draft framing review at C2. |
| Update model | Rolling database updates (weekly curation cycle). Report refresh on publication calendar. | Snapshot-dated per engagement. Staleness banner mandatory after 90 days. T3 quarterly retainer available from Q4 2026 for rolling reads. |
| AI methodology | Disclosed at platform level; AI features layered across Norstella products. Per-product AI use varies. | AI-assisted retrieval and synthesis under documented human oversight; Gate A re-verifies every Sourced claim, Gate B runs LLM-council adversarial review. EU AI Act Article 4 deployer posture disclosed. |
| Buyer fit | Large pharma strategy, BD, clinical operations, market access, site-selection teams who need an always-on multi-asset multi-TA query layer. | Medical affairs, BD search-and-evaluation, small-biotech CMOs, life-sciences analysts who need a single sharp comparator answer with audit-grade citation. |
Delvant is not a database. There is no log-in, no Trialtrove-style trial tracker, no Sitetrove-style investigator layer, no live news flow. If your team needs to query thousands of trials and sites every week, a syndicated stack like Citeline (or GlobalData, Evaluate, Clarivate Cortellis) is the right shape of tool.
Delvant is also not a multi-month strategy consultancy. If your question requires 8-12 weeks of senior advisory time, six interviews per geography, and a EUR 200K+ engagement, you should commission Putnam, Trinity, L.E.K., Health Advances, ZS, or Norstella's own The Dedham Group. Delvant covers the gap between those two: bounded custom work at 5-15 business day turnaround, EUR 3,500-35,000, narrow TA, audit-grade citation.
30-minute scoping call. We will tell you whether a Citeline query answers it, whether a Delvant T1 or T2 fits, or whether you should be talking to a consultancy. Honest fit calls only.
Book a scoping call See engagement tiers